Evidence map›Paper›PMID 27165780›Full record

ArticleScience signaling2016

Gain-of-function mutations in protein kinase Cα (PKCα) may promote synaptic defects in Alzheimer's disease.

Stephanie I Alfonso, Julia A Callender, Basavaraj Hooli, Corina E Antal, Kristina Mullin, Mathew A Sherman, Sylvain E Lesné, Michael Leitges, Alexandra C Newton, Rudolph E Tanzi and 1 more

Expression of concernOpen access · greenAbstract read
In one paragraph

Article in Science signaling, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It carries an expression of concern. Cited by 63 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 3 pooled it
6.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 3 syntheses or guidelines pooled it, 111 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Alzheimer's Pathology Enhances Excitatory Synaptic Input and Integration in VTA Dopamine Neurons.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2026
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Amyloid-β-Driven Synaptic Deficits Are Mediated by Synaptic Removal of GluA3-Containing AMPA Receptors.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Stephanie I AlfonsoDepartment of Neurosciences and Division of Biology, Section of Neurobiology, University of California, San Diego, La Jolla, CA 92093, USA.
Julia A CallenderDepartment of Pharmacology, University of California, San Diego, La Jolla, CA 92093, USA. Biomedical Sciences Graduate Program, University of California, San Diego, La Jolla, CA 92093, USA.
Basavaraj HooliGenetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.
Corina E AntalDepartment of Pharmacology, University of California, San Diego, La Jolla, CA 92093, USA. Biomedical Sciences Graduate Program, University of California, San Diego, La Jolla, CA 92093, USA.
Kristina MullinGenetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.
Mathew A ShermanDepartment of Neuroscience, N. Bud Grossman Center for Memory Research and Care, and Institute for Translational Neuroscience, University of Minnesota, Minneapolis, MN 55414, USA.
Sylvain E LesnéDepartment of Neuroscience, N. Bud Grossman Center for Memory Research and Care, and Institute for Translational Neuroscience, University of Minnesota, Minneapolis, MN 55414, USA.
Michael LeitgesBiotechnology Centre of Oslo, University of Oslo, Oslo 0317, Norway.
Alexandra C NewtonDepartment of Pharmacology, University of California, San Diego, La Jolla, CA 92093, USA. anewton@ucsd.edu tanzi@helix.mgh.harvard.edu rmalinow@ucsd.edu.
Rudolph E TanziGenetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA. anewton@ucsd.edu tanzi@helix.mgh.harvard.edu rmalinow@ucsd.edu.
Roberto MalinowDepartment of Neurosciences and Division of Biology, Section of Neurobiology, University of California, San Diego, La Jolla, CA 92093, USA. anewton@ucsd.edu tanzi@helix.mgh.harvard.edu rmalinow@ucsd.edu.
University of California, San Diego · USMassachusetts General Hospital · USHarvard University · US

Funding

GRADUATE TRAINING IN CELLULAR &MOLECULAR PHARMACOLOGYT32GM007752 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BROWN, JOAN HELLER, HANDEL, TRACY M · 1985 to 2023
$13.5M
Neurosciences Graduate Training ProgramT32NS061847 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Brenda L Bloodgood · 2008 to 2026
$7.7M
Identification and Characterization of Novel AD GenesR37MH060009 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI TANZI, RUDOLPH EMILE · 2003 to 2012
$7.6M
SEARCH FOR NOVEL ALZHEIMERS DISEASE GENESR01MH060009 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI TANZI, RUDOLPH EMILE · 1999 to 2017
$5.4M
MECHANISMS OF SYNAPTIC LTP--SILENT SYNAPSESR01MH049159 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MALINOW, ROBERTO · 1997 to 2019
$4.7M
Novel roles by glutamatergic receptors in the synaptic effects of beta amyloidR01AG032132 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MALINOW, ROBERTO · 2008 to 2017
$4.5M
Structure, Function and Regulation of Protein Kinase CR37GM043154 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI NEWTON, ALEXANDRA C. · 2003 to 2012
$4.0M
STRUCTURE/FUNCTION AND REGULATION OF PROTEIN KINASE CR01GM043154 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI NEWTON, ALEXANDRA C. · 1990 to 2016
$2.5M
Soluble aSyn is a modulator of AD pathophysiologyR01AG044342 · NIA · UNIVERSITY OF MINNESOTA · PI LESNE, SYLVAIN E. · 2014 to 2018
$1.5M
Mechanism of Action of ABeta*56 in Alzheimer's DiseaseR00AG031293 · NIA · UNIVERSITY OF MINNESOTA · PI LESNE, SYLVAIN E. · 2010 to 2012
$693k
NIA NIH HHS R00 AG031293NIA NIH HHS R01 AG032132NIGMS NIH HHS R01 GM043154NIGMS NIH HHS R37 GM043154NIGMS NIH HHS T32 GM007752NIMH NIH HHS R01 MH049159NIMH NIH HHS R01 MH060009NIMH NIH HHS R37 MH060009NINDS NIH HHS T32 NS061847
6 · The paper itself

Abstract

Alzheimer's disease (AD) is a progressive dementia disorder characterized by synaptic degeneration and amyloid-β (Aβ) accumulation in the brain. Through whole-genome sequencing of 1345 individuals from 410 families with late-onset AD (LOAD), we identified three highly penetrant variants in PRKCA, the gene that encodes protein kinase Cα (PKCα), in five of the families. All three variants linked with LOAD displayed increased catalytic activity relative to wild-type PKCα as assessed in live-cell imaging experiments using a genetically encoded PKC activity reporter. Deleting PRKCA in mice or adding PKC antagonists to mouse hippocampal slices infected with a virus expressing the Aβ precursor CT100 revealed that PKCα was required for the reduced synaptic activity caused by Aβ. In PRKCA(-/-) neurons expressing CT100, introduction of PKCα, but not PKCα lacking a PDZ interaction moiety, rescued synaptic depression, suggesting that a scaffolding interaction bringing PKCα to the synapse is required for its mediation of the effects of Aβ. Thus, enhanced PKCα activity may contribute to AD, possibly by mediating the actions of Aβ on synapses. In contrast, reduced PKCα activity is implicated in cancer. Hence, these findings reinforce the importance of maintaining a careful balance in the activity of this enzyme.

Indexed as

MutationAlzheimer DiseaseAnimalsChlorocebus aethiopsCOS CellsFamily HealthGenomeGenome, HumanHippocampusHumansMiceNeoplasmsNeurodegenerative DiseasesProtein DomainsProtein Kinase C-alphaSynapsesPRKCA protein, humanPrkca protein, mouseProtein Kinase C-alpha

Identifiers

PMID27165780
PMCPMC5154619
OpenAlexW2359021079

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.